Citigroup’s Direxion Daily S&P Biotech Bull 3X ETF LABU Stock Holding History
Bought
Maintained
Sold
Other funds holding LABU
JF
TRCT
XT
HF
MIG
TSS
Citigroup's LABU Position: Q1 2026 in Review
Citigroup sold out of Direxion Daily S&P Biotech Bull 3X ETF (LABU) in Q1 2026, closing a stake of 1 share — an estimated $159 sold.
Citigroup first reported a position in LABU in Q2 2015 and held it in 32 quarters. The position peaked at $12.8M in Q3 2017. 33 funds tracked by Wall St. Rank hold LABU as of Q1 2026.
- Citigroup reported no remaining Direxion Daily S&P Biotech Bull 3X ETF position as of Q1 2026 after selling out during the quarter.
- Citigroup sold 1 Direxion Daily S&P Biotech Bull 3X ETF share in Q1 2026, an estimated $159.
- Citigroup first reported a position in Direxion Daily S&P Biotech Bull 3X ETF in Q2 2015 and held it in 32 quarters.
- Citigroup's Direxion Daily S&P Biotech Bull 3X ETF position peaked at $12.8M in Q3 2017.
- 33 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bull 3X ETF as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.